X

Drug Profile

MRTX 7512

Alternative Names: MRTX-7512

Latest Information Update: 25 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mirati Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action PRMT5 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

Highest Development Phases

Preclinical Cancer

Most Recent Events

23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
01 Jul 2021 Mirati Therapeutics plans to file IND application for Cancer, in first-half of 2022
22 Jun 2021 MRTX 7512 is available for licensing as of 22 Jun 2021. https://www.mirati.com/about/business-development/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com